Lyell Immunopharma CMO Jarrad Mattieu Aguirre files initial beneficial ownership statement
LYEL•Initial beneficial ownership filing
- Lyell Immunopharma Chief Medical Officer Jarrad Mattieu Aguirre reported direct ownership of 20,279 common shares in an initial SEC filing.
